Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Economic Evaluation of Infliximab for Treatment of Refractory Ulcerative Colitis in Iran: Cost-Effectiveness Analysis



Moradi N1 ; Tofighi S2 ; Zanganeh M3 ; Sari AA4 ; Khedmat H5 ; Zarei L1
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Health management research center, Baghiatallah University of Medical Sciences, Tehran, Iran
  3. 3. Health insurance office, Ministry of Health and Medical Education, Tehran, Iran
  4. 4. School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Research Center for Gastroenterology and Liver Disease, Baghiatallah University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Pharmaceutical Sciences Published:2016

Abstract

The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients were individuals with moderate to severe UC that are resistant to conventional treatments. Remission rate, clinical response, and surgery were selected as clinical outcomes. For estimating QALY, utility value related to each state, was derived form published paper. We also estimated associated probabilities by using patients ’medical records and specialists’ opinion. Costs of treatment such as Physician visit fee, laboratory tests, hospitalizations, surgery, and drugs were estimated based on the public sector tariffs and drug price list set by pricing committee of food and drug administration. Infliximab costs at dosage of 5 mg/kg were considered for UC patients with average weight of 75 kilogram. Incremental Cost-Effectiveness Ratio (ICER) of infliximab treatment in UC patients were 240,903 USD dollars per QALY gained, compared with conventional treatments. According to recommendation of World Health Organization for choosing cost-effective intervention, interventions with relative cost-effectiveness value less than 3 times of Gross Domestic Production (GDP) per capita, are cost–effective. Our result showed that the ICER value of infliximab is approximately 51 times of Iran’s local GDP per capita, in 2014 – i.e. more than 3 time GDP per capita. Thus, for UC patients, our finding indicates that infliximab is not a cost-effective treatment. © 2016, Iranian Association of Pharmaceutical Scientists. All rights reserved.
Related Docs
1. Intravenous and Subcutaneous Vedolizumab for Moderately to Severely Active Ulcerative Colitis in Iran: A Model-Based Cost-Effectiveness Evaluation, Expert Review of Pharmacoeconomics and Outcomes Research (2025)